Charles K. Tashima
About
In The Last Decade
Charles K. Tashima
50 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 92
- Oncology 572
- Pulmonary and Respiratory Medicine 385
- Cancer Research 245
- Pathology and Forensic Medicine 185
- Surgery 158
Countries citing papers authored by Charles K. Tashima
This map shows the geographic impact of Charles K. Tashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles K. Tashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles K. Tashima more than expected).
Fields of papers citing papers by Charles K. Tashima
This network shows the impact of papers produced by Charles K. Tashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles K. Tashima. The network helps show where Charles K. Tashima may publish in the future.
Co-authorship network of co-authors of Charles K. Tashima
This figure shows the co-authorship network connecting the top 25 collaborators of Charles K. Tashima. A scholar is included among the top collaborators of Charles K. Tashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles K. Tashima. Charles K. Tashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 83 | |
| 3 | 7 | |
| 4 | 23 | |
| 5 | 71 | |
| 6 | 27 | |
| 7 | Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. | 20 |
| 8 | Update on the adjuvant chemoimmunotherapy of stage IV ned breast cancer | 1 |
| 9 | 19 | |
| 10 | Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. | 9 |
| 11 | 171 | |
| 12 | Adriamycin and mitomycin C: possible synergistic cardiotoxicity. | 46 |
| 13 | 7 | |
| 14 | 2 | |
| 15 | Tumor blood-flow study to measure response to treatment. | 1 |
| 16 | 7 | |
| 17 | 1 | |
| 18 | 1 | |
| 19 | 16 | |
| 20 | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.